Published in Clinical Trials Week, December 26th, 2005
In a "multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia" in the United States, the "efficacy and safety of olanzapine were compared with those of ziprasidone."
"Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone," according to A. Breier and coauthors at Lilly Research Laboratories. "The primary efficacy measure was the Positive and Negative Syndrome Scale total score," while "secondary efficacy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.